Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 2
2000 1
2001 1
2002 1
2003 1
2005 1
2006 1
2007 1
2008 2
2011 1
2012 1
2014 2
2015 2
2016 3
2017 2
2018 1
2019 1
2020 3
2021 2
2022 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease.
Schuppan D, Mäki M, Lundin KEA, Isola J, Friesing-Sosnik T, Taavela J, Popp A, Koskenpato J, Langhorst J, Hovde Ø, Lähdeaho ML, Fusco S, Schumann M, Török HP, Kupcinskas J, Zopf Y, Lohse AW, Scheinin M, Kull K, Biedermann L, Byrnes V, Stallmach A, Jahnsen J, Zeitz J, Mohrbacher R, Greinwald R; CEC-3 Trial Group. Schuppan D, et al. Among authors: koskenpato j. N Engl J Med. 2021 Jul 1;385(1):35-45. doi: 10.1056/NEJMoa2032441. N Engl J Med. 2021. PMID: 34192430 Free article. Clinical Trial.
Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease.
Dotsenko V, Tewes B, Hils M, Pasternack R, Isola J, Taavela J, Popp A, Sarin J, Huhtala H, Hiltunen P, Zimmermann T, Mohrbacher R, Greinwald R, Lundin KEA, Schuppan D, Mäki M, Viiri K; CEC-3 Investigators. Dotsenko V, et al. Nat Immunol. 2024 Jul;25(7):1218-1230. doi: 10.1038/s41590-024-01867-0. Epub 2024 Jun 24. Nat Immunol. 2024. PMID: 38914866 Free PMC article. Clinical Trial.
Does oral α-galactosidase relieve irritable bowel symptoms?
Hillilä M, Färkkilä MA, Sipponen T, Rajala J, Koskenpato J. Hillilä M, et al. Among authors: koskenpato j. Scand J Gastroenterol. 2016 Jan;51(1):16-21. doi: 10.3109/00365521.2015.1063156. Epub 2015 Jul 2. Scand J Gastroenterol. 2016. PMID: 26133538 Clinical Trial.
Letter: faecal microbiota transplantation for irritable bowel syndrome. Authors' reply.
Lahtinen P, Jalanka J, Hartikainen A, Mattila E, Hillilä M, Punkkinen J, Koskenpato J, Anttila VJ, Tillonen J, Satokari R, Arkkila P. Lahtinen P, et al. Among authors: koskenpato j. Aliment Pharmacol Ther. 2020 Aug;52(3):557-558. doi: 10.1111/apt.15875. Aliment Pharmacol Ther. 2020. PMID: 32656839 No abstract available.
Nizatidine and gastric emptying in functional dyspepsia.
Koskenpato J, Punkkinen JM, Kairemo K, Färkkilä M. Koskenpato J, et al. Dig Dis Sci. 2008 Feb;53(2):352-7. doi: 10.1007/s10620-007-9898-x. Epub 2007 Aug 9. Dig Dis Sci. 2008. PMID: 17682943 Clinical Trial.
Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome.
Lahtinen P, Jalanka J, Hartikainen A, Mattila E, Hillilä M, Punkkinen J, Koskenpato J, Anttila VJ, Tillonen J, Satokari R, Arkkila P. Lahtinen P, et al. Among authors: koskenpato j. Aliment Pharmacol Ther. 2020 Jun;51(12):1321-1331. doi: 10.1111/apt.15740. Epub 2020 Apr 28. Aliment Pharmacol Ther. 2020. PMID: 32343000 Clinical Trial.
27 results